Distinct urinary metabolic profile of human colorectal cancer

Yu Cheng, Guoxiang Xie, Tianlu Chen, Yunping Qiu, Xia Zou, Minhua Zheng, Binbin Tan, Bo Feng, Taotao Dong, Pingang He, Linjing Zhao, Aihua Zhao, Lisa X. Xu, Yan Zhang, Wei Jia

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

A full spectrum of metabolic aberrations that are directly linked to colorectal cancer (CRC) at early curable stages is critical for developing and deploying molecular diagnostic and therapeutic approaches that will significantly improve patient survival. We have recently reported a urinary metabonomic profiling study on CRC subjects (n = 60) and health controls (n = 63), in which a panel of urinary metabolite markers was identified. Here, we report a second urinary metabonomic study on a larger cohort of CRC (n = 101) and healthy subjects (n = 103), using gas chromatography time-of-flight mass spectrometry and ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry. Consistent with our previous findings, we observed a number of dysregulated metabolic pathways, such as glycolysis, TCA cycle, urea cycle, pyrimidine metabolism, tryptophan metabolism, polyamine metabolism, as well as gut microbial-host co-metabolism in CRC subjects. Our findings confirm distinct urinary metabolic footprints of CRC patients characterized by altered levels of metabolites derived from gut microbial-host co-metabolism. A panel of metabolite markers composed of citrate, hippurate, p-cresol, 2-aminobutyrate, myristate, putrescine, and kynurenate was selected, which was able to discriminate CRC subjects from their healthy counterparts. A receiver operating characteristic curve (ROC) analysis of these markers resulted in an area under the receiver operating characteristic curve (AUC) of 0.993 and 0.998 for the training set and the testing set, respectively. These potential metabolite markers provide a novel and promising molecular diagnostic approach for the early detection of CRC.

Original languageEnglish (US)
Pages (from-to)1354-1363
Number of pages10
JournalJournal of Proteome Research
Volume11
Issue number2
DOIs
StatePublished - Feb 3 2012
Externally publishedYes

Fingerprint

Metabolome
Metabolism
Colorectal Neoplasms
Metabolites
Mass spectrometry
Metabolomics
Molecular Pathology
ROC Curve
Kynurenic Acid
Aminobutyrates
Mass Spectrometry
Putrescine
Healthy Volunteers
Liquid chromatography
Myristic Acid
Polyamines
Aberrations
Citric Acid
Tryptophan
Gas chromatography

Keywords

  • colorectal cancer
  • gas chromatography time-of-flight mass spectrometry
  • metabolic profiling
  • metabonomics
  • ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry
  • urine

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Cheng, Y., Xie, G., Chen, T., Qiu, Y., Zou, X., Zheng, M., ... Jia, W. (2012). Distinct urinary metabolic profile of human colorectal cancer. Journal of Proteome Research, 11(2), 1354-1363. https://doi.org/10.1021/pr201001a

Distinct urinary metabolic profile of human colorectal cancer. / Cheng, Yu; Xie, Guoxiang; Chen, Tianlu; Qiu, Yunping; Zou, Xia; Zheng, Minhua; Tan, Binbin; Feng, Bo; Dong, Taotao; He, Pingang; Zhao, Linjing; Zhao, Aihua; Xu, Lisa X.; Zhang, Yan; Jia, Wei.

In: Journal of Proteome Research, Vol. 11, No. 2, 03.02.2012, p. 1354-1363.

Research output: Contribution to journalArticle

Cheng, Y, Xie, G, Chen, T, Qiu, Y, Zou, X, Zheng, M, Tan, B, Feng, B, Dong, T, He, P, Zhao, L, Zhao, A, Xu, LX, Zhang, Y & Jia, W 2012, 'Distinct urinary metabolic profile of human colorectal cancer', Journal of Proteome Research, vol. 11, no. 2, pp. 1354-1363. https://doi.org/10.1021/pr201001a
Cheng, Yu ; Xie, Guoxiang ; Chen, Tianlu ; Qiu, Yunping ; Zou, Xia ; Zheng, Minhua ; Tan, Binbin ; Feng, Bo ; Dong, Taotao ; He, Pingang ; Zhao, Linjing ; Zhao, Aihua ; Xu, Lisa X. ; Zhang, Yan ; Jia, Wei. / Distinct urinary metabolic profile of human colorectal cancer. In: Journal of Proteome Research. 2012 ; Vol. 11, No. 2. pp. 1354-1363.
@article{84babab8982c419da1ecbcae72bcc2b6,
title = "Distinct urinary metabolic profile of human colorectal cancer",
abstract = "A full spectrum of metabolic aberrations that are directly linked to colorectal cancer (CRC) at early curable stages is critical for developing and deploying molecular diagnostic and therapeutic approaches that will significantly improve patient survival. We have recently reported a urinary metabonomic profiling study on CRC subjects (n = 60) and health controls (n = 63), in which a panel of urinary metabolite markers was identified. Here, we report a second urinary metabonomic study on a larger cohort of CRC (n = 101) and healthy subjects (n = 103), using gas chromatography time-of-flight mass spectrometry and ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry. Consistent with our previous findings, we observed a number of dysregulated metabolic pathways, such as glycolysis, TCA cycle, urea cycle, pyrimidine metabolism, tryptophan metabolism, polyamine metabolism, as well as gut microbial-host co-metabolism in CRC subjects. Our findings confirm distinct urinary metabolic footprints of CRC patients characterized by altered levels of metabolites derived from gut microbial-host co-metabolism. A panel of metabolite markers composed of citrate, hippurate, p-cresol, 2-aminobutyrate, myristate, putrescine, and kynurenate was selected, which was able to discriminate CRC subjects from their healthy counterparts. A receiver operating characteristic curve (ROC) analysis of these markers resulted in an area under the receiver operating characteristic curve (AUC) of 0.993 and 0.998 for the training set and the testing set, respectively. These potential metabolite markers provide a novel and promising molecular diagnostic approach for the early detection of CRC.",
keywords = "colorectal cancer, gas chromatography time-of-flight mass spectrometry, metabolic profiling, metabonomics, ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry, urine",
author = "Yu Cheng and Guoxiang Xie and Tianlu Chen and Yunping Qiu and Xia Zou and Minhua Zheng and Binbin Tan and Bo Feng and Taotao Dong and Pingang He and Linjing Zhao and Aihua Zhao and Xu, {Lisa X.} and Yan Zhang and Wei Jia",
year = "2012",
month = "2",
day = "3",
doi = "10.1021/pr201001a",
language = "English (US)",
volume = "11",
pages = "1354--1363",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Distinct urinary metabolic profile of human colorectal cancer

AU - Cheng, Yu

AU - Xie, Guoxiang

AU - Chen, Tianlu

AU - Qiu, Yunping

AU - Zou, Xia

AU - Zheng, Minhua

AU - Tan, Binbin

AU - Feng, Bo

AU - Dong, Taotao

AU - He, Pingang

AU - Zhao, Linjing

AU - Zhao, Aihua

AU - Xu, Lisa X.

AU - Zhang, Yan

AU - Jia, Wei

PY - 2012/2/3

Y1 - 2012/2/3

N2 - A full spectrum of metabolic aberrations that are directly linked to colorectal cancer (CRC) at early curable stages is critical for developing and deploying molecular diagnostic and therapeutic approaches that will significantly improve patient survival. We have recently reported a urinary metabonomic profiling study on CRC subjects (n = 60) and health controls (n = 63), in which a panel of urinary metabolite markers was identified. Here, we report a second urinary metabonomic study on a larger cohort of CRC (n = 101) and healthy subjects (n = 103), using gas chromatography time-of-flight mass spectrometry and ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry. Consistent with our previous findings, we observed a number of dysregulated metabolic pathways, such as glycolysis, TCA cycle, urea cycle, pyrimidine metabolism, tryptophan metabolism, polyamine metabolism, as well as gut microbial-host co-metabolism in CRC subjects. Our findings confirm distinct urinary metabolic footprints of CRC patients characterized by altered levels of metabolites derived from gut microbial-host co-metabolism. A panel of metabolite markers composed of citrate, hippurate, p-cresol, 2-aminobutyrate, myristate, putrescine, and kynurenate was selected, which was able to discriminate CRC subjects from their healthy counterparts. A receiver operating characteristic curve (ROC) analysis of these markers resulted in an area under the receiver operating characteristic curve (AUC) of 0.993 and 0.998 for the training set and the testing set, respectively. These potential metabolite markers provide a novel and promising molecular diagnostic approach for the early detection of CRC.

AB - A full spectrum of metabolic aberrations that are directly linked to colorectal cancer (CRC) at early curable stages is critical for developing and deploying molecular diagnostic and therapeutic approaches that will significantly improve patient survival. We have recently reported a urinary metabonomic profiling study on CRC subjects (n = 60) and health controls (n = 63), in which a panel of urinary metabolite markers was identified. Here, we report a second urinary metabonomic study on a larger cohort of CRC (n = 101) and healthy subjects (n = 103), using gas chromatography time-of-flight mass spectrometry and ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry. Consistent with our previous findings, we observed a number of dysregulated metabolic pathways, such as glycolysis, TCA cycle, urea cycle, pyrimidine metabolism, tryptophan metabolism, polyamine metabolism, as well as gut microbial-host co-metabolism in CRC subjects. Our findings confirm distinct urinary metabolic footprints of CRC patients characterized by altered levels of metabolites derived from gut microbial-host co-metabolism. A panel of metabolite markers composed of citrate, hippurate, p-cresol, 2-aminobutyrate, myristate, putrescine, and kynurenate was selected, which was able to discriminate CRC subjects from their healthy counterparts. A receiver operating characteristic curve (ROC) analysis of these markers resulted in an area under the receiver operating characteristic curve (AUC) of 0.993 and 0.998 for the training set and the testing set, respectively. These potential metabolite markers provide a novel and promising molecular diagnostic approach for the early detection of CRC.

KW - colorectal cancer

KW - gas chromatography time-of-flight mass spectrometry

KW - metabolic profiling

KW - metabonomics

KW - ultra performance liquid chromatography quadrupole time-of-flight mass spectrometry

KW - urine

UR - http://www.scopus.com/inward/record.url?scp=84863024905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863024905&partnerID=8YFLogxK

U2 - 10.1021/pr201001a

DO - 10.1021/pr201001a

M3 - Article

C2 - 22148915

AN - SCOPUS:84863024905

VL - 11

SP - 1354

EP - 1363

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 2

ER -